EP1477496A1 — Peg-conjugated pth or peg-conjugated pth derivate
Assigned to Chugai Pharmaceutical Co Ltd · Expires 2004-11-17 · 21y expired
What this patent protects
The object of the present invention is to provide PTH or a PTH derivative, which is modified to attain increased bioavailability without losing PTH activity and to have a reduced risk of side effects. PEG conjugation to PTH or a PTH derivative increases the bioavailability while …
USPTO Abstract
The object of the present invention is to provide PTH or a PTH derivative, which is modified to attain increased bioavailability without losing PTH activity and to have a reduced risk of side effects. PEG conjugation to PTH or a PTH derivative increases the bioavailability while maintaining PTH activity and also reduces side effects.
Drugs covered by this patent
- Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.